CAIX-targeted CAR-T Cells for Advanced Renal Cancer

Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma

Recruiting Phase 1 Interventional Study
Immunotherapy
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 70
Sex
Any
Trial phase
Phase 1
Study type
Interventional
Purpose
Treatment
Participants needed
20 (estimated)
Sponsor
The Affiliated Hospital of Xuzhou Medical University · Other
Who this trial is looking for

This trial is looking for adults with advanced renal cancer. Participants will be treated with a new type of immune cell therapy to find out how safe and effective it is.

Are You a Good Fit for This Trial?

You may be able to join if

  • I am between 18 and 70 years old.
  • I have advanced or metastatic renal cell carcinoma.
  • I have previously received certain cancer therapies.
  • I have measurable cancer lesions.
  • My main organs are functioning well.
  • I can sign informed consent.

You may not be able to join if

  • I have an active infectious disease like HIV or hepatitis.
  • My vital signs are abnormal.
  • I have a mental health condition that affects my treatment.
  • I have a severe allergy to IL-2.
  • I have a serious infection that needs treatment.
  • I have dysfunction in important organs like my heart or lungs.
  • I have another type of cancer.
  • My doctor thinks there are other reasons I should not participate.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This is an experimental study to evaluate the safety and efficacy of CAR T cells targeting CAIX in the treatment of advanced renal cancer.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Male or female patients aged from 18 to 70 years old; 2. The patient's ECOG score is ≤ 2; 3. Patients with advanced or metastatic renal cell carcinoma: (1) have received first-line and second-line targeted therapy in the past; (2) Previous immunization with PD-1/L1 and ≤2 re…
Contacts

Hailong Li, M.D/Ph.D

0086-17798835021

Justinlee719@163.com

CONTACT

Qing Zhang, Ph.D

0086-516-83262238

qingzhang@xzhmu.edu.cn

CONTACT